@article{ae6e2de79e5d43bda891328186e3b9a9,
title = "Is going into stable symptomatic remission associated with a more positive development of life satisfaction? A 10-year follow-up study of first episode psychosis",
abstract = "Background: Quality of life is an important outcome measure for patients with psychosis. We investigated whether going into stable symptomatic remission is associated with a more positive development of subjective quality of life (S-QoL) and if different patient characteristics are associated with S-QoL depending on remission status. Methods: Three hundred and one patients with a first-episode psychosis were included at baseline. At 10-year follow-up 186 were reassessed. QoL was assessed by Lehman's Quality of Life Interview. Remission was defined according to criteria proposed by the Remission in Schizophrenia Working Group. One-way ANOVA, mixed model analysis, bivariate correlations and multiple regression analyses were performed. Results: Patients going into stable symptomatic remission showed a more positive S-QoL-development over the follow-up period and reported higher life satisfaction at 10-year follow-up compared to non-remission. At 10-year follow-up, depressive symptoms and alcohol abuse or dependence explained a significant amount of variance in S-QoL among patients in remission. Among patients in non-remission, PANSS excitative component explained a significant amount of variance in S-QoL. All significant effects were negative. Conclusions: Stable symptomatic remission is associated with a more positive development of overall life satisfaction. Furthermore, different symptoms influence life satisfaction depending on status of remission. This has important clinical implications. While patients in remission might need treatment for depressive symptoms to increase S-QoL, in non-remission measures aiming to decrease hostility and uncooperativeness should be part of the treatment approach. Alcohol problems should be treated regardless of remission status.",
keywords = "First episode psychosis, Life satisfaction, Long-term follow-up, Quality of life, Remission, Schizophrenia, Humans, Middle Aged, Male, Quality of Life/psychology, Personal Satisfaction, Young Adult, Regression Analysis, Psychiatric Status Rating Scales, Analysis of Variance, Adolescent, Adult, Female, Aged, Psychotic Disorders/psychology, Longitudinal Studies",
author = "Gardsjord, {Erlend Strand} and Romm, {Kristin Lie} and R{\o}ssberg, {Jan Ivar} and Svein Friis and Barder, {Helene Eidsmo} and Julie Evensen and Ulrik Haahr and {ten Velden Hegelstad}, Wenche and Inge Joa and Johannessen, {Jan Olav} and Johannes Langeveld and Larsen, {Tor Ketil} and Stein Opjordsmoen and Rund, {Bj{\o}rn Rishovd} and Erik Simonsen and Per Vaglum and Thomas McGlashan and Ingrid Melle",
note = "Funding Information: The project has been approved by the Regional Committee for Medical Research Ethics Health Region II (#S-95189) and the Regional Committee for Medical Research Ethics Health Region East (#1.2007.2177). Data Inspectorate (License #96/3017-2 and #2003/2052). Biological data collection approved by Norwegian Directory of Health (#200403453) and the Regional Committee for Medical Research Ethics Health Region East (#493-03-01179). The Regional Committee for Science Ethics region Sj{\ae}lland, Denmark (#1-01-83-0002-07). Supported by Health West, Norway (Wenche ten Velden Hegelstad) (# 911369 ); supported by the Norwegian National Research Council (# 133897/320 and # 154642/320 ), the Norwegian Department of Health and Social Affairs , and the National Council for Mental Health/Health and Rehabilitation (# 1997/41 and # 2002/306 ), Rogaland County and Oslo County (Drs. Vaglum, Johannessen, Friis, Larsen, Melle, Opjordsmoen). Also funded by the Theodore and Vada Stanley Foundation , the Regional Health Research Foundation for Eastern Region, Denmark ; Roskilde County, Helsefonden, Lundbeck Pharma , Eli Lilly and Janssen-Cilag Pharmaceuticals , Denmark (Drs Simonsen and Haahr). Also supported by a National Alliance for Research on Schizophrenia and Depression ( NARSAD ) Distinguished Investigator Award and NIMH grant MH-01654 (Dr. McGlashan) and a NARSAD Young Investigator Award (Dr. Larsen). Health South East (# 2008001 ), Health West (# 200202797-65 ) (Inge Joa) and Regional Centre for Clinical Research in Psychosis (# 911313 ). Publisher Copyright: {\textcopyright} 2017",
year = "2018",
month = mar,
day = "1",
doi = "10.1016/j.schres.2017.07.006",
language = "English",
volume = "193",
pages = "364--369",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}